Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry
Purpose: Constitutional MLH1 epimutations manifest as promoter methylation and silencing of the affected allele in normal tissues, predisposing to Lynch syndrome–associated cancers. This study investigated their frequency and inheritance. Methods: A total of 416 individuals with a colorectal cancer...
Gespeichert in:
Veröffentlicht in: | Genetics in medicine 2013-01, Vol.15 (1), p.25-35 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose:
Constitutional
MLH1
epimutations manifest as promoter methylation and silencing of the affected allele in normal tissues, predisposing to Lynch syndrome–associated cancers. This study investigated their frequency and inheritance.
Methods:
A total of 416 individuals with a colorectal cancer showing loss of MLH1 expression and without deleterious germline mutations in
MLH1
were ascertained from the Colon Cancer Family Registry (C-CFR). Constitutive DNA samples were screened for
MLH1
methylation in all 416 subjects and for promoter sequence changes in 357 individuals.
Results:
Constitutional
MLH1
epimutations were identified in 16 subjects. Of these, seven (1.7%) had mono- or hemi-allelic methylation and eight had low-level methylation (2%). In one subject the epimutation was linked to the c.-27C>A promoter variant. Testing of 37 relatives from nine probands revealed paternal transmission of low-level methylation segregating with a c.+27G>A variant in one case. Five additional probands had a promoter variant without an
MLH1
epimutation, with three showing diminished promoter activity in functional assays.
Conclusion:
Although rare, sequence changes in the regulatory region of
MLH1
and aberrant methylation may alone or together predispose to the development of cancer. Screening for these changes is warranted in individuals who have a negative germline sequence screen of
MLH1
and loss of MLH1 expression in their tumor.
Genet Med
2013:15(1):25–35 |
---|---|
ISSN: | 1098-3600 1530-0366 |
DOI: | 10.1038/gim.2012.91 |